Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Talazoparib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    $ API Ref.Price (USD/KG) : 12,061Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer targets broad Talzenna label in prostate cancer
    Pfizer targets broad Talzenna label in prostate cancer

    11 Oct 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/pfizer-targets-broad-talzenna-approval-prostate-cancer-trial-meets-patient-survival-goal

    FIERCE PHARMA
    11 Oct 2024
    Share Share
    NICE reverses its call on Talzenna after Pfizer discount
    NICE reverses its call on Talzenna after Pfizer discount

    19 Jan 2024

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/after-pfizer-offers-discount-nice-gives-thumbs-breast-cancer-drug-talzenna

    Kevin Dunleavy FIERCE PHARMA
    19 Jan 2024
    Share Share
    EC Approves Pfizer’s TALZENNA®with XTANDI® for Prostate Cancer
    EC Approves Pfizer’s TALZENNA®with XTANDI® for Prostate Cancer

    08 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231221936013/en

    BUSINESSWIRE
    08 Jan 2024
    Share Share
    Pfizer's Talzenna wins broader prostate cancer nod than AZ rival
    Pfizer's Talzenna wins broader prostate cancer nod than AZ rival

    21 Jun 2023

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma/pfizers-talzenna-snags-broader-prostate-cancer-nod-astrazenecas-parp-remains-hopeful-further

    Angus Liu FIERCE PHARMA
    21 Jun 2023
    Share Share
    FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC
    FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC

    20 Jun 2023

    // ONCOLIVE

    https://www.onclive.com/view/fda-approves-talazoparib-plus-enzalutamide-for-hrr-gene-altered-mcrpc

    ONCOLIVE
    20 Jun 2023
    Share Share
    Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
    Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval

    20 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230615555231/en

    BUSINESSWIRE
    20 Jun 2023
    Share Share